Modeling HIV-associated neurocognitive disorders in mice: new approaches in the changing face of HIV neuropathogenesis

被引:33
|
作者
Jaeger, Laura B. [1 ]
Nath, Avindra [1 ]
机构
[1] Natl Inst Neurol Disorders & Stroke, Sect Infect Nervous Syst, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; COAT PROTEIN GP120; TRANSGENIC MICE; HUMANIZED MICE; TAT PROTEIN; NEUROPROTECTIVE ACTIVITIES; ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE;
D O I
10.1242/dmm.008763
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
It is well established that infection with the human immunodeficiency virus (HIV) leads to immune suppression. Less well known is the fact that long-term, progressive HIV disease is associated with the development of cognitive deficits. Since the introduction of combined antiretroviral therapy (cART), the clinical presentation of HIV infection has evolved into a chronic illness with very low levels of viral replication and chronic immune activation, with compliant affected individuals surviving for decades with a high quality of life. Despite these advances, many HIV-infected individuals develop some degree of neurodegeneration and cognitive impairment. The underlying pathophysiological mechanisms are not well understood, and there are no effective treatments. Thus, there is an unmet need for animal models that enable the study of HIV-associated neurocognitive disorders (HAND) and the testing of new therapeutic approaches to combat them. Here, we review the pros and cons of existing mouse models of HIV infection for addressing these aims and propose a detailed strategy for developing a new mouse model of HIV infection.
引用
收藏
页码:313 / 322
页数:10
相关论文
共 50 条
  • [41] Decoding HIV-associated neurocognitive disorders: a new perspective from multimodal connectomics
    Zhou, Zhongkai
    Wang, Wei
    Li, Hui
    Shi, Ying
    Zhao, Lingling
    Lu, Yibo
    Wei, Xingchen
    Li, Hongjun
    FRONTIERS IN NEUROLOGY, 2025, 16
  • [42] HIV-associated neurocognitive disorder
    Clifford, David B.
    Ances, Beau M.
    LANCET INFECTIOUS DISEASES, 2013, 13 (11) : 976 - 986
  • [43] HIV-associated neurocognitive disorder
    Clifford, David B.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2017, 30 (01) : 117 - 122
  • [44] Targeting the Glutamatergic System for the Treatment of HIV-Associated Neurocognitive Disorders
    Potter, Michelle C.
    Figuera-Losada, Mariana
    Rojas, Camilo
    Slusher, Barbara S.
    JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2013, 8 (03) : 594 - 607
  • [45] Signatures of HIV-1 subtype B and C Tat proteins and their effects in the neuropathogenesis of HIV-associated neurocognitive impairments
    Williams, Monray E.
    Zulu, Simo S.
    Stein, Dan J.
    Joska, John A.
    Naude, Petrus J. W.
    NEUROBIOLOGY OF DISEASE, 2020, 136
  • [46] The role of CCR5 in HIV-associated neurocognitive disorders
    Riviere-Cazaux, Cecile
    Cornell, Jessica
    Shen, Yang
    Zhou, Miou
    HELIYON, 2022, 8 (07)
  • [47] HIV-Associated Vacuolar Myelopathy and HIV-Associated Neurocognitive Disorder as an Initial Presentation in HIV Infection
    Asaduzzaman, Md
    Das, Atonu
    Das, Sowmitra
    Shamma, Mahfuza Khadija
    Shoab, Abul Kalam Mohammed
    Kumar Roy, Biplob
    CASE REPORTS IN INFECTIOUS DISEASES, 2023, 2023
  • [48] Developments in Neuroprotection for HIV-Associated Neurocognitive Disorders (HAND)
    Kolson, Dennis L.
    CURRENT HIV/AIDS REPORTS, 2022, 19 (05) : 344 - 357
  • [49] Can Humanized Mice Reflect the Complex Pathobiology of HIV-Associated Neurocognitive Disorders?
    Gorantla, Santhi
    Gendelman, Howard E.
    Poluektova, Larisa Y.
    JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2012, 7 (02) : 352 - 362
  • [50] HIV-Associated Neurocognitive Disorders: Perspective on Management Strategies
    Linda Nabha
    Lan Duong
    Joseph Timpone
    Drugs, 2013, 73 : 893 - 905